Top news of November: Multi-food immunotherapy, climate crisis, COVID-19, more
Click Here to Manage Email Alerts
Healio compiled the most-read news in allergy, asthma and immunology posted in November.
Innovative research presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Anaheim, California, dominated our coverage, including studies on COVID-19 hospitalization, ChatGPT and an immunotherapy toothpaste. Other popular topics included a multi-food oral immunotherapy, climate change and tezepelumab (Tezspire; Amgen, AstraZeneca).
FDA grants fast track designation to multi-food oral immunotherapy
Alladapt Immunotherapeutics’ ADP101 targets multiple food allergies in patients by including almond, cashew, chicken egg, codfish, cow milk, hazelnut, peanut, pecan, pistachio, salmon, sesame seed, shrimp, soy, walnut and wheat. Read more.
200 health journals call separation of climate, biodiversity crises ‘dangerous mistake’
More than 200 health journals simultaneously published an editorial calling on the United Nations, political leaders and health professionals to recognize how climate change and biodiversity are a single global health emergency. Also, Kari C. Nadeau, MD, shares her Perspective. Read more.
Saltwater gargling, nasal rinsing associated with lower COVID-19 hospitalization
After gargling and nasal rinsing with saline solution four times a day for 14 days, hospitalization rates included 18.5% in the low-saline group and 21.4% in the high-saline group, compared with 58.8% in the reference group, according to a presentation at the ACAAI Annual Scientific Meeting. Read more.
ChatGPT accurately, yet sometimes inconsistently, debunks many allergy myths
ChatGPT answered accurately 70% of the time or somewhat accurately 21% of the time when asked about 10 allergy myths on topics such as pets, anaphylaxis, early allergen introduction and flu vaccines, Ricardo J. Estrada-Mendizabal, MD, reported at the ACAAI Annual Scientific Meeting. Read more.
Immunotherapy toothpaste shows promise for treatment of peanut allergy
INT301 from Intrommune Therapeutics was developed specifically to avoid the need for ingestion, which is associated with increased risk for adverse events, William E. Berger, MD, MBA, said during the ACAAI Annual Scientific Meeting. Read more.
Incoming ACAAI president sees three trends impacting asthma, allergy care
Gailen D. Marshall Jr., MD, PhD, FACP, FACAAI, said that artificial intelligence and telehealth will benefit practices and patients alike, but the push for more productivity in consolidated and group practices may present challenges. Read more.
Popular TikTok videos illustrate autoinjector fears
The 15 most popular videos on TikTok about autoinjector fears have more than 5 million likes, but none of the creators of these videos appeared to be health care providers or have any kind of medical background, Tori Martel, MPH, said during the ACAAI Annual Scientific Meeting. Read more.
Asthma associated with lower mortality among patients hospitalized for COVID-19
Patients with asthma had 35% lower odds for mortality of COVID-19 than those with no airway disease, and patients with eosinophil counts of 200 cells/µL or higher also had lower odds for mortality, according to a study published in The Journal of Allergy or Clinical Immunology: In Practice. Read more.
Tezepelumab reduces asthma exacerbations season by season
Exacerbations fell across all seasons for patients with seasonal and perennial allergies alike, including a 59% decrease in the spring allergy season and a 70% decrease in the ragweed allergy season, researchers reported in Annals of Allergy, Asthma & Immunology. Read more.
Allergists can guide patients through medical waivers in military enlistment
Although allergies and asthma can be disqualifying for patients who want to enlist in the military, physicians can provide documentation and help candidates file for waivers that would enable them to serve, Karla Adams, MD, FACAAI, said during the ACAAI Annual Scientific Meeting. Read more.